Source: Annual Congress 2006 - Epidemiology of susceptible, resistant and multidrug-resistant tuberculosis (MDR-TB)
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. Törün, K. Tahaoglu, I. Özmen, G. K. Güngör, T. Sevim, G. Ataç, E. Aksoy, G. Gündüz (Istanbul, Turkey). Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2006; 28: Suppl. 50, 2263

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Long-term results of multidrug-resistant tuberculosis treatment. Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Source: Eur Respir J 2013; 41: 1393-1400 Year: 2013 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009